<DOC>
	<DOCNO>NCT00008398</DOCNO>
	<brief_summary>RATIONALE : Sargramostim may lessen symptom mucositis patient receive radiation therapy head neck cancer . It yet know sargramostim effective treatment reduce mucositis cause radiation therapy . PURPOSE : Randomized phase III trial determine effectiveness sargramostim decrease mucositis patient receive radiation therapy head neck cancer .</brief_summary>
	<brief_title>Sargramostim Decreasing Mucositis Patients Receiving Radiation Therapy Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy sargramostim ( GM-CSF ) term reduce severity expect duration radiotherapy-induced oral mucositis patient head neck cancer receive radiotherapy . - Determine correlation reduce mucosal injury quality life improvement patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord concurrent cisplatin chemotherapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive radiotherapy daily five day week 6-7 week . Patients also receive sargramostim ( GM-CSF ) subcutaneously ( SC ) three time week ( except day receive concurrent cisplatin ) begin 1 week prior radiotherapy continue 2 week completion radiotherapy total approximately 9 week . - Arm II : Patients receive radiotherapy arm I . Patients also receive placebo SC schedule GM-CSF arm I . Quality life assess baseline , 3 , 6 , 12 month . Patients follow 3 , 6 11 month . PROJECTED ACCRUAL : A total 126 patient ( 63 per arm ) accrue within 1.2-1.4 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm head neck carcinoma plan external beam radiotherapy include 50 % oropharynx , oral cavity , ] Planned external beam radiotherapy 6070 Gy total dose primary tumor standard port unknown primary tumor Neck metastases unknown primary allow radiotherapy plan least 50 % salivary gland dose least 50 Gy No T1T2 glottic tumor No residual oral/oropharyngeal injury prior chemotherapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy idiosyncratic response sargramostim ( GMCSF ) HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy cisplatin Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy head neck Surgery : Not specify Other : No concurrent enrollment RTOG head neck study No concurrent oral care medication ( e.g. , amifostine , chlorhexidrine gluconate , sucralfate , benzydamine HCl ) study radiotherapy No concurrent selective oral cavity decontamination ( e.g. , IB367 ) study radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage I nasopharyngeal cancer</keyword>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>stage 0 paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage 0 nasopharyngeal cancer</keyword>
	<keyword>stage 0 oropharyngeal cancer</keyword>
	<keyword>stage 0 laryngeal cancer</keyword>
	<keyword>stage 0 hypopharyngeal cancer</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage 0 lip oral cavity cancer</keyword>
	<keyword>stage I lip oral cavity cancer</keyword>
	<keyword>stage II lip oral cavity cancer</keyword>
	<keyword>stage III lip oral cavity cancer</keyword>
	<keyword>stage IV lip oral cavity cancer</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>stage I hypopharyngeal cancer</keyword>
	<keyword>stage II hypopharyngeal cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage I paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage II paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage III paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage IV paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage I oropharyngeal cancer</keyword>
	<keyword>stage II oropharyngeal cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
	<keyword>oral complication</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>